CRO businessClinical trials of pharmaceuticals, medical devices, regenerative medicine, etc.Clinical researchPost‑marketing surveillanceDatabase researchDatabase research supportClinical development (clinical trials, physician‑initiated trials)Clinical research (interventional studies, observational studies, surveys)Post‑marketing surveillance (PMS)Safety information management (GVP)Database research and studiesMedical information and customer centerAdverse event spontaneous reporting database (FAERS/JADER)Global services
Names without a link are companies not yet registered in OpenBizGraph
§05
Network
NETWORK
Loading the relationship graph...
Drag to move · click to open
§06
History
47 EVENTS
1992 IBRD JAPAN Inc. Establishment
Established IBRD JAPAN Inc.
In 2000, all shares of IBRD JAPAN Co., Ltd. were transferred to the Social Research Institute Co., Ltd. (renamed Intage Co., Ltd. in 2001) and became a 100% subsidiary.
All shares of IBRD JAPAN Inc. were transferred to the Social Survey Research Institute Co., Ltd. (renamed Intage Co., Ltd. in 2001) and became a 100% subsidiary
In 2003, the Medical Solutions Division of IBRD JAPAN Co., Ltd. and Intage Co., Ltd. was merged, and the company name was changed to Asclep Co., Ltd.
Integrated the medical solutions division of IBRD JAPAN Inc. and Intage Co., Ltd. and simultaneously changed the company name to Asklep Co., Ltd.
In 2004, EDC solution services for post‑marketing surveillance were launched.
Started providing EDC solution services for post‑marketing surveillance
In 2008, a strategic license grant and development agreement with XClinical (Germany) was signed, and the EDC system "MARVIN" was introduced.
In 2008, a strategic partnership agreement with overseas CROs was signed, and global operations were fully launched.
Signed a strategic licensing and development agreement with XClinical (Germany) and implemented the EDC system "MARVIN"
Entered a strategic partnership agreement with an overseas CRO and fully launched global operations
In 2010, a local subsidiary was established in China (ASKLEP CHINA Inc. / 阿思克瑞普医药諮詢(上海)有限公司).
Established a local subsidiary in China (ASKLEP CHINA Inc.)
2012 PPCJ Inc. absorbed and merged
2012 Established a local subsidiary in Taiwan (Taiwan ASKLEP Biotech Consulting Co., Ltd. / ASKLEP TAIWAN Inc.)
2012 Established a local subsidiary in Korea (아스크랩코리아 / ASKLEP KOREA Inc.)
Absorbed and merged with PPCJ Co., Ltd.
Established a local subsidiary in Taiwan (ASKLEP TAIWAN Inc.)
Established a local subsidiary in South Korea (ASKLEP KOREA Inc.)
2013 Established RPS Asklep Inc. (JVC) in Korea
Established RPS Asklep Inc. (JVC) in South Korea
2014 Divided the clinical development business and related operations to ATE Health Care Co., Ltd. (new corporation). At the same time, transferred shares of the corporation, overseas local subsidiaries (China, Taiwan, Korea), and RPS Asklep Inc. to Itochu Corporation
Divided the clinical development business and related activities to ATE Health Care Co., Ltd. (new corporation). At the same time, transferred shares of the company, overseas local subsidiaries (China, Taiwan, South Korea), and RPS Asklep Inc. to Itochu Corporation
2015 Capital and business alliance with Kyoto Constellation Technologies
2015 Released new version "ADDIN EX" of the post-manufacturing survey EDC "ADDIN"
Entered a capital and business alliance with Kyoto Constellation Technologies
Released a new version "ADDIN EX" of the post-manufacturing sales investigation EDC "ADDIN"
2016 Capital and business alliance with Assembly Log Co., Ltd.
2016 Kyoto Constellation Technologies Co., Ltd. became a subsidiary
Entered a capital and business alliance with Assembly Org Co., Ltd.
Made Kyoto Constellation Technologies a subsidiary
2018 Launched patient association support service using the eCOQOLO app
2018 Participated in Kyoto University’s one‑stop bio resource project "KBBM Co., Ltd."
2018 Joined a consortium that supports the entire process from clinical development to sales for pharmaceutical and medical device companies
Launched a "Patient Association Support Service" using the app "eCOQOLO"
Participated in the one-stop bio-resource business "KBBM Co., Ltd." at Kyoto University
Joined a consortium that supports pharmaceutical and medical device companies from clinical development to sales in a one-stop manner
2019 Merged Asklep Co., Ltd. and Antelio Co., Ltd., both part of the Intage Group’s healthcare division, and established Intage Healthcare Co., Ltd.
Intage Group’s healthcare division, Asklep Co., Ltd. and Antelio Co., Ltd. merged to establish Intage Healthcare Co., Ltd.
2024 Divested CRO business from Intage Healthcare to ArkMS Co., Ltd. (new corporation). At the same time, became a full subsidiary of Alphressa Holdings Co., Ltd.
Divided the CRO business from Intage Healthcare to ArkMS Co., Ltd. (new corporation) and fully acquired by Alfresa Holdings Co., Ltd.
Established ArkMS Co., Ltd.
2026 Signed a business transfer agreement with Remedia Co., Ltd.
2026 Signed a business alliance agreement with M-Wiz Co., Ltd.
Signed a business transfer agreement with Remedia Co., Ltd.
Signed a business alliance agreement with M-Wiz Co., Ltd.
§07
News
10 ARTICLES
Microsoft 365 Outage Impacting Inquiries
Due to a Microsoft 365 system outage, emails addressed to ArkMS Inc. may not be received. Submissions via the website contact form may also fail to be received. For urgent matters, please call us. We will provide updates on the recovery status as soon as possible.
Notice of Resumption of Contact Form Acceptance
The contact form that was temporarily suspended has been restored and is now available for use as usual. We have instructed those who contacted us during the suspension period to contact us again. We apologize for any inconvenience caused.
Notice of Temporary Suspension of the Contact Form (Resolved)
Currently, due to a system outage, we are unable to receive messages from the contact form, so we have temporarily suspended its operation. We will notify you again once the issue is resolved.
Contact Form Restored
The contact form, which had been temporarily unavailable due to a system failure, was restored on August 24, 2026. It is now available for use as usual.
Notice of Osaka Office Relocation
ArkMS Co., Ltd.'s Osaka office will begin operations at its new address (5th Floor, Honmachi Highest Building, 4-7-5 Awajimachi, Chuo-ku, Osaka, Osaka Prefecture) on July 16, 2026. The company says that all employees will strive to do even better following the relocation.
President Interview Featured in Pharmaceutical Daily Report 'CRO/SMO Special'
An interview article featuring ArkMS Co., Ltd.'s President and CEO, Naoto Mizuo, was published in the Pharmaceutical Daily Report 'CRO/SMO Special' issued on June 29, 2026. The article introduces the expansion of specialized areas of CRO services and ArkMS's CRO functions in the Alfressa Group's 'TSCS'.
Notice of Information Disclosure under the Worker Dispatch Law
In accordance with Article 23, Paragraph 5 of the Worker Dispatch Act, we are publishing information about our worker dispatch business. The margin rate for fiscal year Reiwa 6 is listed.
Notice of New Year's Holiday
The company will be closed from Saturday, December 27, 2025, to Sunday, January 4, 2026, for the New Year's holiday. We appreciate your understanding.
Head Office Relocation Notice
ArkMS Corporation has relocated its headquarters to enhance the quality of communication and provide better services. Operations at the new office will commence on November 4, 2025, and the location is 13th floor, Hareza Tower, 1-18-1 Higashi-Ikebukuro, Toshima-ku, Tokyo.
Announcement of Osaka Office Relocation
ArkMS Corporation's Osaka office began operations at its new address on February 14, 2025. The new address is 6-38 Oosumachi, Kita-ku, Osaka City, Osaka Prefecture, Grangreen Osaka North Building, JAM BASE 3rd floor, JAM STUDIO 305.
§08
Public records
GOV
National Tax Agency basic information9013301053062
Source: National Tax Agency Corporate Number Publication Site, basic three items
Trade name
ArkMS株式会社
Trade name (kana)
アークメディカルソリューションズ
Name in English
Corporation type
301
Address
〒170-0013 東京都豊島区東池袋1丁目18番1号
Postal code
1700013
Prefecture code
13
City code
116
Address outside Japan
Prefecture in English
City in English
Address outside Japan in English
Corporate number assignment date
2024-09-11
Update date
2025-11-13
Change date
2025-11-04
Registry closure date
Reason for registry closure
Successor corporate number
Details of the change
Latest record
1
Excluded from search
0
Processing type
12
Correction type
0
Trade name image ID
Address image ID
Sequence number
2599831
METI gBizINFO9013301053062
Source: gBizINFO (Ministry of Economy, Trade and Industry)